AzTrials
AzTrials

Chronic Limb-Threatening IschemiaEspritBTKPASNCT06656364

Esprit BTK Post-Approval Study

A study testing Esprit BTK System in people with Chronic Limb-Threatening Ischemia, run by Abbott Medical Devices at 39 sites in 4 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Chronic Limb-Threatening Ischemia
What is being tested?
Esprit BTK System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
39 sitesin 4 countries
Study dates
21 Oct 2024to 30 May 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • General Inclusion Criteria
  • Subject must provide written informed consent prior to any study-specific procedures which are not considered standard of care at the site.
  • Informed consent can be obtained up to 3 days post-procedure or prior to discharge whichever comes first.
  • Subject, or a legally acceptable representative must provide written informed consent per site IRB/EC requirements.
  • Subject must be at least 18 years of age.
  • Subject has evidence of symptomatic Chronic Limb-Threatening Ischemia (CLTI) with infrapopliteal lesions.
Show all 9Show fewer
  • Anatomic Inclusion Criteria
  • Subjects who have lesion(s) in an infrapopliteal vessel with reference vessel diameter ≥ 2.5 mm and ≤ 4.0 mm.
  • Target lesion(s) must have ≥ 70% stenosis, per visual assessment at the time of the procedure. If needed, quantitative imaging (angiography and intravascular imaging) can be used to aid accurate sizing of the vessels.

Who cannot join

  • General Exclusion Criteria
  • Subjects who have contraindications to the Esprit BTK System per the instruction for use (IFU).
  • Subject is currently participating in another clinical investigation that has not yet completed its primary endpoint.
  • Subject or Legally Acceptable Representative (LAR) is unable or unwilling to provide written consent prior to enrollment.
  • Subject with life expectancy ≤ 1 year.
  • Subject with an unsalvageable limb (as per physician assessment at the time of the index procedure), who is likely to get a below-the-knee amputation.
Show all 9Show fewer
  • Anatomic Exclusion Criteria
  • Subject has in-stent restenosis in the target vessel or requires a metallic stent as part of a planned treatment or a bailout in the target vessel during the index procedure.
  • Subject had been previously treated with Esprit BTK Scaffold(s) within the past 30 days in the same vessel.

Trial locations and contacts

39 sites in 4 countries.

39 sites in 4 countries

United States36 sites
  • Hendrick Medical Center

    Abilene, Texas, 79601

  • Medical City Arlington

    Arlington, Texas, 76014

  • Grady Clinical Research Center

    Atlanta, Georgia, 30303

  • Ascension St. John Jane Phillips

    Bartlesville, Oklahoma, 74006

  • Carolinas Medical Center

    Charlotte, North Carolina, 28203

  • Erlanger Medical Center

    Chattanooga, Tennessee, 37403

  • Christ Hospital

    Cincinnati, Ohio, 45255

  • University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas, 75390

  • ClinRé 001-100 - Denver

    Denver, Colorado, 80220

  • Charlton Memorial Hospital

    Fall River, Massachusetts, 02720

  • Baylor All Saints Medical Center at Fort Worth

    Fort Worth, Texas, 76104

  • UCSF Fresno

    Fresno, California, 93720

  • HCA Houston Healthcare Medical Center

    Houston, Texas, 77004

  • St. Vincent Hospital

    Indianapolis, Indiana, 46260

  • Jackson Heart Clinic

    Jackson, Mississippi, 39216

  • First Coast Cardiovascular Institute

    Jacksonville, Florida, 32256

  • Johnson City Medical Center Hospital

    Johnson City, Tennessee, 37604

  • Good Samaritan Hospital

    Los Angeles, California, 90017

  • Sorin Medical

    New York, New York, 10005

  • New York University Hospital

    New York, New York, 10016

  • NYU Langone Health

    New York, New York, 10016

  • Mount Sinai Hospital

    New York, New York, 10019

  • New York Presbyterian Hospital-Cornell University

    New York, New York, 10021

  • New York-Presbyterian/Columbia University Medical Center

    New York, New York, 10032

  • Hightower Clinical

    Oklahoma City, Oklahoma, 73102

  • Oklahoma Heart Hospital

    Oklahoma City, Oklahoma, 73120

  • St. Francis Hospital

    Roslyn, New York, 11576

  • Ansaarie Cardiac and Endovascular Center of Excellence

    Saint Augustine, Florida, 32080

  • HonorHealth

    Scottsdale, Arizona, 85258

  • SIU School of Medicine

    Springfield, Illinois, 62794

  • Staten Island University Hospital - North

    Staten Island, New York, 10305

  • Tallahassee Research Institute

    Tallahassee, Florida, 32308

  • Cardiovascular Consultants of South Georgia, LLC

    Thomasville, Georgia, 31792

  • Pima Heart and Vascular Clinical Research

    Tucson, Arizona, 85718

  • North Mississippi Medical Center

    Tupelo, Mississippi, 38801

  • Washington Hospital Center

    Washington D.C., District of Columbia, 20010

Other trials in United States

Hong Kong1 site
  • Queen Mary Hospital

    Hong Kong, HK SAR, 999077

Other trials in Hong Kong

New Zealand1 site
  • Auckland City Hospital

    Auckland, 1003

Other trials in New Zealand

United Arab Emirates1 site
  • Al Qassimi Hospital

    Sharjah city, Emirate of Sharjah, 3500

Other trials in United Arab Emirates

About this study

Official title: Esprit BTK Post-Approval Study (Esprit BTK PAS)

The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.

Being tested
Esprit BTK System
Keywords
ABT-CIP-10519, Esprit BTK System, Infrapopliteal lesions, Post-approval study
Medical subject headings
Chronic Limb-Threatening Ischemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Esprit BTK SystemDevice

    The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.

Study groups in NCT06656364
Study groupRoleWhat they receive
Esprit BTK SystemExperimentalThis device, manufactured by Abbott Medical, is intended to be used for improving luminal diameter in infrapopliteal lesions in patients with CLTI.
Receives: Device: Esprit BTK System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Effectivenes Endpoint(s): Freedom from clinically-driven target lesion revascularization (CD-TLR)

    This effectiveness endpoint was chosen because it allows to assess whether Esprit BTK is effective at maintaining patency (CD-TLR).

    Measured: At 1 year

  2. Primary Safety Endpoint(s):MALE at 6 months + POD at 30 days (Major Adverse Limb Event + Peri-Operative Death)

    This safety endpoint was chosen because it is a commonly used endpoint to assess the safety of devices used in lower limb treatment, including treatment of lesions below the knee. Additionally, this endpoint assesses whether the device is associated with acute and sub-acute harm such as death and limb loss.

    Measured: 6 months + 30 days

Secondary outcomes (6)
  1. All-cause mortality

    Death was classified according to the underlying cause. Death within 30 days of the study procedure was classified as procedure-related unless medical history or autopsy findings demonstrated otherwise.

    Cardiac death: Any death due to a proximate cardiac cause (e.g., MI, low-output failure, fatal arrhythmia), unwitnessed death, or death of unknown cause. Vascular death: Death caused by noncoronary vascular causes, such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular diseases. Non-cardiovascular death: Any death not covered by the above definitions, such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide, or trauma.

    Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years

  2. Amputation (minor, major)

    The definition of amputation applied only to amputations of the limb that was treated. Minor amputation referred to toe amputation(s), ray amputation(s) limited to the metatarsal head and distal half of the metatarsal bone, and trans-metatarsal amputation. Major amputation was defined as limb loss at or proximal to the transtibial level. Major amputations were specified as below-the-knee and above-the-knee amputations.

    Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years

  3. Amputation-free survival

    Freedom from above-ankle amputation in the treated limb and death

    Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years

  4. Ankle-Brachial Index (ABI)/Toe-Brachial Index (TBI) progression over time

    The ABI was the ratio of the ankle to arm pressure, and it was calculated by dividing the systolic blood pressure in the ankle of one leg by the higher of the two systolic blood pressures in the arms.

    An ABI of 0.9-1.4 was considered within the normal range. A reduced ABI (less than 0.9) was consistent with peripheral artery occlusive disease, with values below 0.8 indicating moderate disease and values below 0.5 indicating severe disease. A value greater than 1.4 was considered abnormal, suggesting calcification of the arterial walls and noncompressible vessels, reflecting severe peripheral vascular disease.

    Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years

  5. Rutherford Becker category evolution over time

    The Rutherford Becker classification was defined as follows: Grade I (0) Asymptomatic, no hemodynamically significant occlusive disease. (1)Mild claudication. (2) Moderate claudication. (3) Severe claudication. Grade II (4)Ischemic rest pain. Grade III(5) Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia. (6) Major tissue loss extending above the transmetatarsal level, where the functional foot was no longer salvageable.

    Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years

  6. Wound healing, as assessed by investigator

    An index wound healing assessment log was required only for subjects who had a wound on the index limb at the time of the index procedure. This was intended to allow the healing of the index wound after treatment to be documented. All subjects that had a wound at the time of the index procedure are required to have an assessment by the site at each follow-up visit even if the index wound was healed at the previous visit. This will confirm that the index wound remains healed. If the index wound at the same location following healing has re-opened, the wound should still be assessed in the same index wound log.

    Measured: Discharge (between 0 and 10-days post-index procedure), 30 days, 90 days (only for subjects with index wound), 6 months, 1 year, 2 years, 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Oct 2024
  2. Study start21 Oct 2024
  3. Primary completion30 Apr 2027 (estimated)
  4. Study completion30 May 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06656364
Sponsor's protocol ID
ABT-CIP-10519
Acronym
EspritBTKPAS
Status last verified
Mar 2026
First submitted
15 Oct 2024
Last updated
25 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Esprit BTK System in people with Chronic Limb-Threatening Ischemia, run by Abbott Medical Devices at 39 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 25 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 39 sites in United States, Hong Kong, New Zealand, United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Effectivenes Endpoint(s): Freedom from clinically-driven target lesion revascularization (CD-TLR) (time frame: At 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in